Physician profile
Eric A Osborn
NPI 1548445240
$58,482.11
in general payments reported to CMS, 2019-2025
9 companies · $11K in 2025
The $11K reported for 2025 was more than what 89% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2021: $3,214 · 2022: $104 · 2023: $10K · 2024: $16K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $33K · Honoraria: $2,700 · Food and Beverage: $314 · Travel and Lodging: $273 · Entertainment: $88.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $33,493.59 |
| Honoraria | $2,700.00 |
| Food and Beverage | $313.80 |
| Travel and Lodging | $272.62 |
| Entertainment | $88.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gentuity, LLC | $27,712.99 | 2023-2025 | Gentuity Hf-Oct Imaging System, Vis-Rx, Vis-Rx Prime |
| Abbott Laboratories | $18,574.78 | 2019-2022 | |
| Opsens INC. | $4,475.85 | 2021-2023 | Savvywire, Optowire |
| Philips North America LLC | $3,392.33 | 2021-2024 | (9520) Igt Devices Undivided |
| Abiomed | $2,700.00 | 2023 | Impella |
| Cardiva Medical, INC. | $1,500.00 | 2024-2025 | Optowire, Savvywire |
| Actelion Pharmaceuticals US, INC. | $67.49 | 2025 | Opsynvi, Uptravi |
| Getinge USA Sales, LLC | $58.67 | 2021-2025 | Cardiosave Rescue |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Osborn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.